Beaconlight Capital’s Haemonetics HAE Stock Holding History

Beaconlight Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-39,626	Closed	-$2.51M	–	45
2022 Q1	$2.51M	Buy	+39,626	New	+$2.15M	0.79%	29
2021 Q4	–	Sell	-68,682	Closed	-$4.85M	–	47
2021 Q3	$4.85M	Sell	68,682 -23,868	-26%	-$1.51M	2.12%	20
2021 Q2	$6.17M	Sell	92,550 -63,845	-41%	-$4.52M	2.2%	20
2021 Q1	$17.4M	Buy	156,395 +13,401	+9%	+$1.66M	2.8%	8
2020 Q4	$17M	Buy	142,994 +49,954	+54%	+$5.38M	5.15%	7
2020 Q3	$8.12M	Sell	93,040 -1,993	-2%	-$174K	2.91%	13
2020 Q2	$8.51M	Sell	95,033 -128,580	-58%	-$13M	2.84%	16
2020 Q1	$22.3M	Buy	+223,613	New	+$24.2M	5.93%	6
2018 Q1	–	Sell	-92,317	Closed	-$5.36M	–	22
2017 Q4	$5.36M	Sell	92,317 -36,900	-29%	-$1.94M	1.97%	13
2017 Q3	$5.8M	Buy	+129,217	New	+$5.37M	3.06%	10

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beaconlight Capital's HAE Position: Q2 2022 in Review

Beaconlight Capital sold out of Haemonetics (HAE) in Q2 2022, closing a stake of 39,626 shares — an estimated $2.51M sold.

Beaconlight Capital first reported a position in HAE in Q3 2017 and held it in 10 quarters. The position peaked at $22.3M in Q1 2020. 241 funds tracked by Wall St. Rank hold HAE as of Q2 2022.

Beaconlight Capital reported no remaining Haemonetics position as of Q2 2022 after selling out during the quarter.
Beaconlight Capital sold 39,626 Haemonetics shares in Q2 2022, an estimated $2.51M.
Beaconlight Capital first reported a position in Haemonetics in Q3 2017 and held it in 10 quarters.
Beaconlight Capital's Haemonetics position peaked at $22.3M in Q1 2020.
241 funds tracked by Wall St. Rank held Haemonetics as of Q2 2022.

Based on Beaconlight Capital's 13F filing for Q2 2022, filed 15 Aug 2022.